Xinos Jaime 4

What Happened
Jaime Xinos, Chief Commercial Officer of Achieve Life Sciences (ACHV), was granted a derivative award for 180,000 shares on January 28, 2026. The grant is reported at $0.00 (no cash paid) and is recorded as a derivative security (an option award). This is an award/grant rather than a purchase or sale.

Key Details

• Transaction date: January 28, 2026; reported consideration: $0.00 per share (derivative award).
• Quantity: 180,000 shares (option award).
• Vesting: 25% vests on the first anniversary and the remainder vests in substantially equal monthly installments over the next 36 months (see footnote F1).
• Shares owned after the transaction: Not disclosed on the Form 4.
• Filing: Form 4 was filed January 30, 2026 (appears to be filed within the typical two-business-day window).

Context
This was a time‑based option award to an executive, not an open‑market buy or sale. The award vests over four years, so the shares are not immediately owned or liquid; exercise and any subsequent sale would occur only as portions vest and subject to the plan’s terms. Awards like this are common for executive compensation and do not by themselves indicate an immediate bullish or bearish trading signal.